Mostrar el registro sencillo del ítem

Neuroinflammation: A therapeutic target of cotinine for the treatment of psychiatric disorders?

dc.contributor.authorEcheverria V.
dc.contributor.authorGrizzell J.A.
dc.contributor.authorBarreto G.E.
dc.date.accessioned2020-09-02T22:17:30Z
dc.date.available2020-09-02T22:17:30Z
dc.date.issued2016
dc.identifier10.2174/138161282210160304112511
dc.identifier.citation22, 10, 1324-1333
dc.identifier.issn13816128
dc.identifier.urihttps://hdl.handle.net/20.500.12728/4459
dc.descriptionNeuroinflammation is a common characteristic of several mental health conditions such as major depression, bipolar disorder, post-traumatic stress disorder (PTSD) and schizophrenia (SCHZ). Inflammatory processes trigger and/or further deteriorate mental functions and are regarded as targets for therapeutic drug development. Cotinine is an alkaloid present in tobacco leaves and the main metabolite of nicotine. Cotinine is safe, non-addictive and has pharmacokinetic properties adequate for therapeutic use. Research has shown that cotinine has antipsychotic, anxiolytic, and antidepressant properties and modulates the serotonergic, cholinergic and dopaminergic systems. Consistent with the modulation of these neurotransmitter systems, cotinine behaves as a positive allosteric modulator of the nicotinic acetylcholine receptors (nAChRs) and has anti-inflammatory effects. The decrease in neuroinflammation induced by the stimulation of the cholinergic system seems to be a key element explaining the beneficial effects of cotinine in a diverse range of neurological and psychiatric conditions. This review discusses new evidence of the role of neuroinflammation as a key aspect in bipolar disorder, PTSD and major depression, as well as the potential use of cotinine to reduce neuroinflammation in those conditions. © 2016 Bentham Science Publishers.
dc.language.isoen
dc.publisherBentham Science Publishers B.V.
dc.subjectAnxiety
dc.subjectBipolar disorder
dc.subjectCotinine
dc.subjectMajor depression
dc.subjectNeuroinflammation
dc.subjectPost-traumatic stress disorder
dc.subjectSuicide
dc.subjectcotinine
dc.subjectnicotinic receptor
dc.subjectcotinine
dc.subjectdyes, reagents, indicators, markers and buffers
dc.subjectneuroleptic agent
dc.subjectanxiety disorder
dc.subjectArticle
dc.subjectbipolar disorder
dc.subjectdrug mechanism
dc.subjectfear
dc.subjecthuman
dc.subjectmajor depression
dc.subjectmental disease
dc.subjectmental stress
dc.subjectmeta analysis (topic)
dc.subjectnervous system inflammation
dc.subjectnonhuman
dc.subjectposttraumatic stress disorder
dc.subjectpriority journal
dc.subjectsuicidal behavior
dc.subjectanimal
dc.subjectbipolar disorder
dc.subjectcomplication
dc.subjectDepressive Disorder, Major
dc.subjectimmunology
dc.subjectinflammation
dc.subjectStress Disorders, Post-Traumatic
dc.subjectAnimals
dc.subjectAntipsychotic Agents
dc.subjectBipolar Disorder
dc.subjectCotinine
dc.subjectDepressive Disorder, Major
dc.subjectHumans
dc.subjectIndicators and Reagents
dc.subjectInflammation
dc.subjectStress Disorders, Post-Traumatic
dc.titleNeuroinflammation: A therapeutic target of cotinine for the treatment of psychiatric disorders?
dc.typeArticle


Ficheros en el ítem

Thumbnail
Nombre:
item_2-s2.0-84961689598.pdf
Tamaño:
3.359Kb
Formato:
PDF
Ver/

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem